DrugBiological
Varlilumab clinical trials
Also written CDX-1127.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 7
Celldex Therapeutics (3) · National Cancer Institute (NCI) (1) · Annick Desjardins, MD (1) · University Hospital Southampton NHS Foundation Trust (1) · Craig L Slingluff, Jr (1) · Rutgers, The State University of New Jersey (1) · Nicholas Butowski (1) · James Larner, MD (1)
Often tested with
Tested in the same studies.
Diphtheria-Tetanus Vaccine (1) · Atezolizumab (1) · Glembatumumab vedotin (1) · CDX-301 (1) · flt3 ligand protein (1) · Ipilimumab (1) · Rasdegafusp alfa (1) · Poly ICLC (1)
Studies
Open first, then newest update. How each study uses varlilumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03038672Written as Varlilumab
- DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabActive, not recruitingPhase 2Annick Desjardins, MDNCT03688178Written as Varlilumab
- Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCTerminatedPhase 1Rutgers, The State University of New JerseyNCT04081688Written as Varlilumab 3 mg/kg
- A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell LymphomaCompletedPhase 1/2University Hospital Southampton NHS Foundation TrustNCT03307746Written as Varlilumab
- A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)TerminatedPhase 1Nicholas ButowskiNCT02924038Written as Varlilumab
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCompletedPhase 1/2Craig L Slingluff, JrNCT03617328Written as CDX-1127
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotin and varlilumab
- Pilot Study of SBRT and CDX-1127 in Prostate CancerTerminatedPhase 1James Larner, MDNCT02284971Written as CDX1127
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedPhase 1Celldex TherapeuticsNCT01460134Written as CDX-1127
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedPhase 1/2Celldex TherapeuticsNCT02413827Written as Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
Given in every arm · 1 — varlilumab is usual care beside what is tested
Codes
What other systems call varlilumab · ClinicalTrials.gg INT000769
- MeSH (NLM) C000622120varlilumabOne source NLM
- UNII (FDA) 0125DUV5XCVARLILUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q21098904VarlilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99127VarlilumabOne source FDA
- DrugBank DB11930One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622120 | varlilumab | One source NLM |
| UNII (FDA) | 0125DUV5XC | VARLILUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098904 | Varlilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99127 | Varlilumab | One source FDA |
| DrugBank | DB11930 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.